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Background: Alternative treatment of dehydration
is needed when intravenous (IV) or oral rehydration
therapy fails. Subcutaneous (SC) hydration facilitated
by recombinant human hyaluronidase offers an alter-
native treatment for dehydration. This clinical trial is
the first to compare recombinant human hyaluroni-
dase-facilitated SC (rHFSC) rehydration with standard
IV rehydration for use in dehydrated children.
Objective: This Phase IV noninferiority trial evalu-
ated whether rHFSC fluid administration can be given
safely and effectively, with volumes similar to those
delivered intravenously, to children who have mild to
moderate dehydration.
Methods: The study included mild to moderately
dehydrated children (Gorelick dehydration score) aged
1 month to 10 years. They were randomized to receive
20 mL/kg of isotonic fluids using rHFSC or IV therapy
over 1 hour and then as needed until clinically rehy-
drated. The primary outcome was total volume of fluid
administered (emergency department [ED] plus inpa-
tient hospitalization). Secondary outcomes included
mean volume infused in the ED alone, postinfusion
dehydration scores and weight changes, line placement
success and time, safety, and provider and parent/
guardian questionnaire.
2232Results: 148 patients (mean age, 2.3 [1.91] years];
white, 53.4%; black, 31.8%) were enrolled in the in-
tention-to-treat population (73 rHFSC; 75 IV). The
primary outcome, mean total volume infused, was
365.0 (324.6) mL in the rHFSC group over 3.1 hours
versus 455.8 (597.4) mL in the IV group over 6.6 hours
(P  0.51). The secondary outcome of mean volume
infused in the ED alone was 334.3 (226.40) mL in the
rHFSC group versus 299.6 (252.33) mL in the IV
group (P  0.03). Dehydration scores and weight
changes postinfusion were similar. Successful line
placement occurred in all 73 rHFSC-treated patients
and 59 of 75 (78.7%) IV-treated patients (P 
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P.R. Spandorfer et al.0.0001). All IV failures occurred in patients aged 3
years; rHFSC rescue was successful in all patients in
whom it was attempted. Both treatments were well
tolerated. Clinicians rated fluid administration as easy
to perform in 94.5% (69 of 73) of the rHFSC group
versus 65.3% (49 of 75) of the IV group (P  0.001).
Parents/caregivers were satisfied or very satisfied with
fluid administration in 94.5% (69 of 73) of rHFSC-
treated patients and 73.3% (55 of 75) of IV-treated
patients.
Conclusions: In mild tomoderately dehydrated chil-
dren, rHFSC was inferior to IV hydration for the pri-
mary outcome measure. However, rHFSC was nonin-
ferior in the ED phase of hydration. Additional benefits
of rHFSC included time and success of line placement,
ease of use, and satisfaction. SC hydration facilitated
with recombinant human hyaluronidase represents a
reasonable addition to the treatment options for
children who have mild to moderate dehydration,
especially those with difficult IV access. ClinicalTrials.
gov identifier: NCT00773175. (Clin Ther. 2012;34:
232–2245) © 2012 Elsevier HS Journals, Inc.
Key words: dehydration, pediatric, rehydration, re-
ombinant human hyaluronidase, subcutaneous.
INTRODUCTION
Assessment and treatment of dehydration is one of the
leading causes of emergency department (ED) use in
the United States.1 Furthermore, dehydration is one of
he most common reasons for hospitalizations in pedi-
trics nationwide. The current standard for treatment
f dehydration is oral rehydration therapy (ORT) and
ntravenous (IV) therapy. However, both therapeutic
echniques have advantages and disadvantages. Ad-
antages of ORT include that it is a more “natural”
ay to rehydrate the patient because it uses the body’s
nherent mechanism to maintain hydration (glucose
odium cotransport), is less expensive, takes less time,
nd can be performed outside of the medical environ-
ent. However, for success, a cooperative patient and
amily are needed. Studies have shown that there is an
pproximate 20% rate of inability to perform ORT.2
IV fluid therapy is obviously a mainstay of rehydration
but requires IV access. It is known that placement of an
IV line is not an easy process, particularly in a dehy-
drated pediatric patient. Research regarding difficult
Open access under CC BY-NC-ND license.IV access has shown that children aged3 years are at
November 2012a greater risk for numerous IV attempts to obtain suc-
cessful placement.3 The disadvantages inherent in
hese 2 techniques necessitate a reevaluation of the
herapeutic options available for dehydrated patients.
ubcutaneous (SC) hydration was established as safe
nd effective for adults and children with dehydration,
nd was commonly used for this purpose in the past
ut was not in widespread use at the time the trial
iscussed herein was conducted.4 SC hydration was
hown to be even more effective with the use of hy-
luronidase, an enzyme that breaks down hyaluro-
an.5 Hyaluronan is a mucopolysaccharide found in
the intracellular matrix of most types of connective
tissue that resists the spread of substances through
the SC space. By temporarily increasing the permea-
bility of hyaluronan, fluid can more readily be ab-
sorbed via the capillary and lymphatic systems after
SC administration.
Development of a recombinant human hyaluroni-
dase* has renewed interest in SC delivery.5 Recombi-
ant human hyaluronidase is a human, DNA-derived,
yaluronidase enzyme that has up to 100 times greater
urity than the reference standard, animal-derived
ormulation, on the basis of enzymatic activitiy.5,6
Recombinant human hyaluronidase-facilitated SC
(rHFSC) rehydration is safe and well tolerated, with no
reports of serious hypersensitivity reactions.7–15 Not
nly did the addition of recombinant human hyaluron-
dase increase gravity-driven SC flow rates 4-fold to
400 mL/hour, but the fluid was absorbed into the
ystemic circulation better than in the control group
ho received SC hydration without recombinant hu-
an hyaluronidase.7 In the first study of rHFSC fluid
dministration, a single-arm, open-label treatment
tudy in mild to moderately dehydrated children (In-
reased Flow Utilizing Subcutaneously-Enabled Pe-
iatric Rehydration I [INFUSE-Peds I]), fluid admin-
stration was well tolerated, and 94.1% of the 51 pa-
ients studied were rehydrated successfully via the SC
oute.13
Potential advantages of rHFSC rehydration com-
pared with IV rehydration are that it expedites and
simplifies parenteral access, requires fewer staff re-
sources, and is less distressing to parents and pa-
tients.13 rHFSC fluid therapy may be particularly use-
ful for patients with difficult IV access. The US Food
*Trademark: Hylenex® Recombinant (Halozyme Therapeutics,
San Diego, California).
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binant human hyaluronidase and issued the same class
label as the existing animal-derived product. One la-
beling restriction was that there was a limit of 200 mL
of fluid that could be administered subcutaneously in
infants and children3 years old. This low amount of
fluid would not be particularly helpful in rehydrating
patients; therefore, the investigators designed the In-
creased Flow Utilizing Subcutaneously-Enabled Pedi-
atric Rehydration II (INFUSE-Peds II) study to evalu-
ate whether rHFSC fluid administration can be given
safely and effectively, with volumes comparable with
those delivered intravenously, in mild to moderately
dehydrated children. The FDA removed the fluid re-
striction while the clinical trial was in progress. The
primary outcome was total fluid administered at a sin-
gle location. Secondary outcomes included mean fluid
volume administered in the ED, dehydration scores,
fluid administration times, pain measures, and line
placement success and questionnaires of the parent/
guardian and health care provider.
METHODS
Study Design
This was a Phase IV, prospective, randomized, in-
dustry-sponsored, multicenter, open-label, parallel-
group, noninferiority clinical trial comparing rHFSC
with IV rehydration. The trial was conducted in 24 US
hospitals with pediatric EDs and 1 urgent-care center
between November 2008 and December 2009. All in-
vestigators received written institutional review board
approval.
The authors chose a noninferiority design to dem-
onstrate that SC hydration is an appropriate alterna-
tive to IV hydration. There are inherent benefits to SC
hydration over IV hydration. If the trial could demon-
strate that SC therapy rehydrates children as well as IV
therapy then the clinician may be willing to use this
option in the future. It would have been inappropriate
to try to demonstrate that SC therapy is superior to IV
therapy because the IV method is considered the “gold
standard” for rehydration. SC hydration may be as
effective and at least as well tolerated as IV hydration
but with fewer potential complications and advantages
in terms of ease of administration; SC hydration may
thus be preferred for appropriately selected patients.
Because SC hydration, compared with IV hydration,
requires less skill to implement and can be delivered in
more patient care settings (eg, settings outside the hos-
2234pital), it may also have an impact on the cost of health
care.
During the course of this study, the FDA approved
several labeling changes for recombinant human hyal-
uronidase that included removal of the upper limit of
fluid volume (200 mL) per SC administration to chil-
dren 3 years of age. Based on the new labeling, the
protocol was amended to include children up to 10
years of age so that the study results could better rep-
resent the pediatric population in whom SC rehydra-
tion is most likely to be used.
Treatments
Patients meeting inclusion and exclusion criteria
(Table I) were randomly assigned to treatment by
using a validated computerized interactive response
system that could be accessed by telephone or an
Internet Web page; patients were stratified according
to dehydration severity and weight. They were ran-
domized 1:1 to rHFSC or IV fluid administration to
1 of 6 different strata. Strata included: weight10.0
kg and mildly dehydrated; weight 10.0 kg and
oderately dehydrated; weight 10.0 kg to 20.0 kg
nd mildly dehydrated; weight 10.0 kg to 20.0 kg
nd moderately dehydrated; weight 20.0 kg to
30.0 kg and mildly dehydrated; or weight 20.0
kg to30.0 kg and moderately dehydrated. Isotonic
fluids were administered at 20 mL/kg16,17 during the
first hour, with additional fluids administered for up
to 72 hours based on the investigator’s ongoing eval-
uation of the patient’s hydration status. Follow-up
telephone assessments occurred on days 2 and 7 after
patient discharge.
Outcome Measures
The primary outcome was mean total fluid volume
(in milliliters) administered at a single infusion site
from start to cessation of fluid administration (ED plus
inpatient hospital stay). The goal was to assess out-
comes from the ED stay alone as well as the entire
encounter (ie, both the ED and inpatient stay com-
bined), if applicable. Prespecified secondary outcomes
for ED alone and ED plus inpatient hospitalization
included total fluid volume and administration times.
Objective improvement in dehydration was assessed
by using a dehydration score (Gorelick 10-item scale18)
and weight change at the end of infusion. Successful
hydration was also subjectively assessed by a health
care provider (HCP) survey at patient discharge. Num-
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P.R. Spandorfer et al.ber of attempts and time required for catheter place-
ment were measured. Pain was assessed by using the
FLACC19 scale (Face, Legs, Activity, Cry, Consolabil-
ty scale; for those 3 years old) and the FACES Pain
ating20 scale (for those 3 years old). HCP and par-
nt/guardian satisfaction with therapy were assessed
ia a simple questionnaire administered by the study
ite investigator at the end of rHFSC or IV rehydration.
reatment-related events, including pain and swelling,
ere noted after catheter placement and hyaluronidase
dministration but before fluid infusion. A serious ad-
erse event (SAE) was defined as any event that was
atal or life-threatening, required inpatient hospitaliza-
Table I. Inclusion and exclusion criteria for the Incre
hydration II (INFUSE-Peds II) study.
Inclusion criteria
● Children aged from 1 month to 10 years
X No more than 20% of enrolled patients will be 
● Patients presenting at the ED, inpatient pediatric un
moderate dehydration (mild  1–2; moderate  3–
dehydration status]) who failed to improve or are n
otherwise candidates for parenteral rehydration pro
X No more than 70% of enrolled patients have a di
X The child is healthy except for the underlying etio
X Prehydration weight 5th percentile for age
X Parents or legal guardian(s) available to provide
Exclusion criteria
● Patients with body weight 30 kg
● Shock or life-threatening situation (life expectancy 
● Requirement for IV access for any indication other t
● Indwelling IV catheter, except if intended only for co
● Any condition precluding SC infusion or infusion-sit
the upper back, anterior thighs, abdomen, and othe
● Any reason (before study enrollment) for a hospital
dehydration
● Known hypersensitivity to hyaluronidase or any ingr
hyaluronidase
● Known hyponatremia (130 mEq/L), hypernatremi
● Any medical condition likely to interfere with the pa
interventions, the ability to undergo all protocol-spe
for medical attention beyond that required for rehyd
● Participation in a study of any investigational drug o
ED  emergency department; IV  intravenous; SC  subcion or prolongation of existing hospitalization, re- t
November 2012ulted in persistent or significant disability/incapacity,
r caused a congenital anomaly/birth defect. Investiga-
ors had a scale onwhich to grade relatedness of SAE to
reatment, including “no, not related,” “unlikely,”
possibly,” “probably,” and “yes, related.” The Na-
ional Cancer Institute’s Terminology Criteria for Ad-
erse Events and Common Toxicity Criteria, a stan-
ard for clinical trials, was used in this study.
At investigator’s discretion, patients could be
witched (“rescued”) to the other treatment after at
east 1 failed attempt. Rescued patients were consid-
red successfully treated if discharged from the ED or,
f admitted for further rehydration, received all addi-
Flow Utilizing Subcutaneously-Enabled Pediatric Re-
rs of age
d/or outpatient urgent-care facility with mild to
sed on the score using the Gorelick assessment of
didates for oral rehydration therapy or are
that:
is of mild dehydration
or dehydration (eg, viral gastroenteritis)
n informed consent
ays)
r treatment of dehydration
n of laboratory specimens
luation in all possible anatomic locations, including
ential areas for SC therapy
ssion or an extended stay in the ED for other than
t in the study formulation of recombinant human
55 mEq/L), or hypokalemia (3.0 mEq/L)
s ability to fully complete all protocol-specified
assessments, or likely to prolong the patient’s need
n
ice within 30 days before enrollment in this study
us.ased
3 yea
it, an
6 [ba
ot can
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logy f
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utaneoional fluid via the rescue route.
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Clinical TherapeuticsStatistical Analysis
This noninferiority study was powered to test the
null hypothesis that rHFSC therapy is inferior to IV
therapy (ie, mean volume infused subcutaneously was
85% of volume delivered intravenously for fluids de-
livered for up to 72 hours). Assuming that fluids could
be administered equivalently via the rHFSC or IV route
and the coefficient of variation for fluid volume admin-
istered was 35%, rHFSC administration would not be
deemed clinically inferior if the volume infused via the
rHFSCmethodwas85%of volume infused by the IV
method. A sample size of 74 patients per group would
provide 80% power at a 1-sided 0.025 level of sig-
nificance for establishing noninferiority of rHFSC ver-
sus IV. A P value of0.05 rejects the null hypothesis of
inferiority.
Descriptive statistics and/or frequency counts for ef-
ficacy measures were analyzed according to: (1) ran-
domized route of administration (all patients) or inten-
tion-to-treat (ITT) population; (2) randomized route
of administration (excluding those switched to another
route before start of infusion) or per-protocol popula-
tion; and (3) patients switched to another route before
start of infusion (rescued population). For some end
points, the second and third analysis groups were com-
bined to yield a comprehensive “treatment-received”
group. This comprehensive treatment-received group
was created post hoc because it was noted that this was
left out of the original analysis plan. This post hoc
group did not change any of the results; however, the
authors felt it was a more true representation of the 2
treatment groups and that the data would be informa-
tive for readers. There were no adjustments for multi-
plicity of testing of the same variable(s) being con-
ducted on multiple populations. The results are
presented based on the ITT population to maintain
research integrity; however, the other 2 populations
are discussed as well for completeness.
ITT Analysis
The ITT population represents all patients random-
ized to receive either rHFSC or IV treatment. Accord-
ing to ITT principles, patients were analyzed according
to randomized treatment even if they received therapy
via the alternate rescue route. Patients in whom infu-
sion device access could not be obtained had values
imputed to the minimum or maximum, however pre-
specified. Patients with unsuccessful access to the ran-
domized route were rescued and their data summa- I
2236rized separately (first according to the randomized
group, second to the rescued group, and third to the
treatment-received group). The ED treatment analysis
includes analysis of treatment in the ED only, whether
discharged from the ED or hospitalized.
RESULTS
Patient Disposition
A total of 148 patients were randomly assigned to 1
of 2 treatment groups (Figure 1); 73 rHFSC-treated
patients and 75 IV-treated patients (ITT population).
Of the 75 patients randomized to receive IV therapy,
15 were rescued to rHFSC (rescued population) before
fluid infusion because successful IV access was not es-
tablished; 1 IV-treated patient was withdrawn from
the study at parent request after 2 IV attempts. All 73
patients randomized to rHFSC had an SC line, and 59
patients randomized to the IV group had an IV line
placed successfully (per-protocol population). Eighty-
eight patients received their first hydration fluid by the
rHFSC route and 59 by the IV route (treatment-re-
ceived population).
Characteristics of Study Patients
The patient population (Table II) was similar with
the exception of patients in the group aged 1 month
to 1 year, which had twice as many patients in the
HFSC group versus the IV group (rHFSC group, 23
31.5%]; IV group, 12 [16.0%]). Because this was a
andomized trial, this randomization difference oc-
urred purely by chance. Mean patient age was 2.3
ears (range, 0.2–9.8 years), and the white popula-
ion (53.4%) and black population (31.8%) were
redominant. Most patients were aged 3 years
79.6%) and weighed 20 kg (95.3%), with a sim-
lar male:female ratio. Approximately 70% of pa-
ients in both groups had moderate dehydration
Gorelick score, 3–6).
Efficacy Results
Total Volume
The primary outcomemeasure, mean (SD) total vol-
ume infused in the ITT population (ED plus inpatient),
was 365.0 (324.57) mL or 31.2 (24.17) mL/kg via the
rHFSC route (n 73) delivered over 3.1 hours (mean)
versus 455.8 (597.43) mL or 35.8 (52.43) mL/kg de-
livered via the IV route (n  75) over 6.6 hours (P 
.51), which was insufficient to reject the null hypoth-
sis that rHFSC is inferior to IV administration (Table
II). The mean duration of infusion difference occurred
Volume 34 Number 11
P.R. Spandorfer et al.because few patients were hospitalized for continued
rehydration with an SC line in place. Thirteen of 73
rHFSC-treated patients and 8 of 59 IV-treated patients
were transferred from the ED to the hospital. Of these,
2 of the rHFSC-treated patients continued an SC line,
whereas the other 11 rHFSC-treated patients had an IV
line placed. Most participating centers did not have
protocols or training for the inpatient staff to manage
an SC line and subsequently had an IV line placed
on admission, explaining this route change. Conse-
quently, more inpatients received fluids intravenously.
When specifically assessing the patients who were hos-
pitalized, the volume discrepancy becomes clear. The 8
hospitalized IV-treated patients had a mean volume of
1464 (1005.6) mL whereas the 2 rHFSC-treated pa-
Enr
N =
Successful in
placement via ra
Successful in
placement via
Physician felt patient su
ED discharge
Randomized to receive rHFSC therapy
n = 73
Home
n = 59
Inpatient‡
n = 9
Home§
n = 1
Inpatient 
n = 4
Yes
n = 73
Yes
n = 68
No
n = 0
No
n = 5
Figure 1. Patient flow. rHFSC recombinant human
ED  emergency department. *One patien
after 2 failed IV attempts and before any rH
parent request, and 1 patient switched to
cessfully hydrated via randomized route and
event judged unrelated to study medicatio
therapy in the ED because of a dislodged c
dislodged catheter. All switched to IV hydra
ted for continued rehydration with rHFSC
primarily for exacerbation of asthma; #Five
cessfully hydrated in ED but admitted primtients contributed a mean volume of 1121 (859.8) mL.
November 2012Analysis of ED-only volumes in the ITT population
reveals that the SC route was shown to be noninferior
in the ED with a mean (SD) volume of 334.3 (226.40)
mL or 28.7 (16.52) mL/kg (rHFSC, n 73) and 299.6
(252.33) mL or 22.2 (16.68) mL/kg (IV, n  75 [P 
0.03]) (Figure 2; Table III). Figure 3 represents fluid
received in the ED and inpatient settings in the per-
protocol population but removes the 16 patients with
failed IV access in the IV groupwho had “0” entered as
the fluid received. The analysis favors IV therapy but is
a more appropriate comparison between rHFSC and
IV therapy. The volumes in milligram per kilogram are
also shown in Table III.
All 15 rHFSC-rescued patients were 3 years old;
their response was similar to patients randomized to
device
zed route
device
 route
ully hydrated
ation
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s withdrawn (WD) from the study at parent request
rescue attempt; †One patient was WD from study at
because of IV infiltration; ‡All 9 patients were suc-
itted primarily for observation (1 for a serious adverse
stroenteritis]); §Patient switched from rHFSC to IV
er; One patient switched to IV therapy because of a
efore or during hospitalization; ¶One patient admit-
e patient successfully hydrated in ED but admitted
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randomized to the SC group.
Other Assessments
Infusion-Device Placement
The number of unsuccessful attempts for infusion-
device placement was higher with IV versus rHFSC
therapy (P  0.01). The rate of successful line place-
ment in the IV group was 78.7% (59 of 75) versus
100% (73 of 73) in the rHFSC group (P 0.0001). All
IV failures were in patients 3 years of age (Figure 4).
Overall, fewer staff members were required for
rHFSC administration. Two staff members were re-
quired to place the infusion device in 49.3% (36 of 73)
of rHFSC-treated patients and 57.6% (34 of 59) of
IV-treated patients. One individual alone placed the
infusion device in 27.4% (20 of 73) of rHFSC-treated
patients and 1.7% (1 of 59) of IV-treated patients.
Three or more personnel were required for placement
Table II. Demographic and baseline clinical characte
Variable
rH
(n
Mean (SD) age, y 2.1
Age group, no. (%)
1 mo to 1 y 23
1 y to 2 y 20
2 y to 3 y 17
3 y 13
Sex, no. (%)
Male 34
Female 39
Race, no. (%)
Black or African American 25
White 39
Other 9
Mean (SD) baseline body weight, kg 11.8
Gorelick dehydration score, no. (%)
Mild (1–2) 20
Moderate (3–6) 53
rHFSC  recombinant human hyaluronidase-facilitated sub
*There were no significant differences except for the 1-montof the infusion device in the remainder of patients.
2238Gorelick Scores and Weight
Objective measures of dehydration were compara-
ble. Mean (SD) reduction from baseline dehydration
score at the end of infusion (ITT population) was 2.6
(1.26) in the rHFSC group (n  73) and 2.2 (1.64) in
the IV group (n  75) (P  0.07) (Table III). Mean
ercent increase in weight from baseline to end of in-
usion in the ITT population was 2.9% (2.52%) in the
HFSC group (n  68) and 3.8% (15.17%) in the IV
group (n  67) (P  0.62). No difference between
treatment groups was seen in time from start of fluid
infusion to first urine output in the ED (2.3 hours with
rHFSC rehydration vs 2.9 hours with IV rehydration).
Subjective Assessment of Hydration Success
Successful hydration, defined according to the
HCPs’ subjective assessment of the randomized route
of hydration therapy (ITT population), was 93.2% (68
of 73) and 76.0% (57 of 75) in the rHFSC and IV
in the intention-to-treat population.*
)
IV
(n  75)
Total
(N  148)
2) 2.4 (2.07) 2.3 (1.91)
5) 12 (16) 35 (23.6)
4) 28 (37.3) 48 (32.4)
3) 18 (24.0) 35 (23.6)
8) 17 (22.7) 30 (20.3)
6) 39 (52.0) 73 (49.3)
4) 36 (48.0) 75 (50.7)
2) 22 (29.3) 47 (31.8)
4) 40 (53.3) 79 (53.4)
3) 13 (17.3) 22 (14.9)
4) 12.9 (4.68) 12.4 (4.44)
4) 23 (30.7) 43 (29.1)
6) 52 (69.3) 105 (70.9)
eous; IV intravenous.
1-year group.ristics
FSC
 73
(1.7
(31.
(27.
(23.
(17.
(46.
(53.
(34.
(53.
(12.
(4.1
(27.
(72.
cutan
h togroups, respectively (P 0.07). All 15 rHFSC-rescued
Volume 34 Number 11
Table III. Primary (volume) and secondary efficacy outcomes.
Outcome
rHFSC IV P or 95% CI
Randomized (ITT)
Population
(n  73)
Patients Switched
From IV to rHFSC
(Rescued
Population)
(n  15)*
Post hoc Treatment-Received
Population Analyses
(n  88)†
Randomized
(ITT)
Population
(n  75)
Patients Who Received
Fluids via Randomized
IV Route
(Per-Protocol
Population)
(n  59)‡
Overall Between
Randomized
(ITT)
Populations
Randomized rHFSC
(n  73) Versus IV
Excluding Rescued
Population
(n  59)
Post hoc
Treatment-
Received
Population rHFSC
(n  88)† Versus IV
(n  59)
Mean (SD) volume
infused in the ED plus
inpatient hospital
stay, mL
365.0 (324.57) 388.3 (281.13) 369.0 (316.19) 455.8 (597.43) 579.4 (618.49) 0.51 0.89 0.866
Mean (SD) volume
infused in the ED plus
inpatient hospital stay
in mL/kg§
31.2 (24.17) 38.6 (25.96) 32.4 (24.47) 35.8 (52.43) 45.9 (55.35) Difference:
2.8; 95% CI,
16.2 to 10.7
Difference:
11.3; 95% CI,
25.9 to 3.3
Difference:
9.8; 95% CI,
23.3 to 3.7
Mean (SD) volume
infused during ED
stay, mL
334.3 (226.40) 315.3 (150.38) 331.0 (214.73) 299.6 (252.33) 380.8 (223.08) 0.03 0.55 0.588
Mean (SD) volume
infused during ED stay,
mL/kg§
28.7 (16.52) 31.5 (14.79) 29.1 (13.33) 22.2 (16.68) 28.4 (13.33) Difference:
6.2; 95% CI,
0.7 to 11.8
Difference:
0.1; 95% CI,
5.3 to 5.5
Difference:
0.4; 95% CI,
4.8 to 5.5
Mean (SD) Gorelick
dehydration score at
end of infusion
0.6 (0.83) 0.3 (0.62) 0.6 (0.80) 0.9 (1.45) 0.3 (0.56) 0.09 0.03 0.048
Mean (SD) Gorelick
dehydration score
change from baseline
at end of infusion
2.6 (1.26) 3.1 (1.22) 2.7 (1.26) 2.2 (1.64) 2.8 (1.34) 0.07 0.51 0.73
rHFSC  recombinant human hyaluronidase-facilitated subcutaneous; IV  intravenous; ITT  intention to treat; ED  emergency department.
*One patient withdrew before receiving fluids.
†The treatment-received group was combined post hoc to show the combined results of the patients who actually received rHFSC and IV therapy (rescue treatment group plus the per-protocol group).
‡Data pertain to IV.
§Three rHFSC randomized, 1 rHFSC rescued, and 2 IV patients had known volumes but missing data on weight (n  70 rHFSC; n  57, IV; and n  14, rescued).
n  58 patients.
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Clinical Therapeuticspatients were considered by the HCP to be successfully
hydrated by using the rescue route.
Infusion Rates
Mean (SD) flow rate observed in the ITT population
(ED plus hospital) was 15.4 (5.62) mL/kg/h in the
rHFSC group (n  70) and 12.3 (9.50) mL/kg/h in the
V group (n 73) (difference, 2.9; 95%CI, 0.3 to 5.5).
n the ED alone, mean flow rate was 15.6 (5.33) mL/
g/h in the rHFSC group and 13.3 (9.50) mL/kg/h in
he IV group (difference 2.2; 95% CI, 0.2 to 4.7).
ean flow rates in the per-protocol population were
imilar to values in the ITT population.
Treatment Times
Less time was required for rehydrating the rHFSC
group. Median total treatment time (first catheteriza-
tion attempt to end of infusion) via the randomized
route in the ITT population was shorter (1.3 hours) for
rHFSC compared with IV hydration (2.3 hours) (P 
.0001) and was the same in the ED plus inpatient and
D only. Median time from first catheterization at-
empt to start of fluid infusion in the ITT population
as shorter (3.5 minutes [rHFSC, n  73] vs 11.8
M
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V
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e 
(m
L)
500
365.0 mL
334.3
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(n = 73)
IV
(n = 75)
P = 0.0325
30.7
165.2
299.6
Hospital stay
ED only
464.8 mL
400
300
200
100
0
Administration Route
Figure 2. Total volume delivered in the emergency
department (ED) was similar between
recombinant human hyaluronidase-fa-
cilitated subcutaneous (rHFSC) and in-
travenous (IV) routes of administration.minutes [IV, n  75]; P  0.001).
2240HCP and Parent/Caregiver Assessments
In the ITT population, HCPs rated fluid administra-
tion as easy to perform in 94.5% (69 of 73) of the
rHFSC group versus 65.3% (49 of 75) of the IV group
(P  0.001), and rHFSC administration less difficult
han IV administration (78.1% [57 of 73]). Parents/
aregivers were satisfied or very satisfied with fluid ad-
inistration in 94.5% (69 of 73) of rHFSC-treated
atients and 73.3% (55 of 75) of IV-treated patients.
Safety Profile
Serious Adverse Events
SAEs were reported in 8 patients (rHFSC, 3; IV, 5).
One SAE fatality was an episode of cardiopulmonary
arrest in a 2-month-old black male (4.5 kg) fromGam-
bia. He was admitted to the ED with a 2-week history
of diarrhea that had been treated with amoxicillin and
metronidazole, with the last dose 72 hours before en-
rollment into the trial. The patient was dehydrated on
evaluation in the ED and enrolled. He received rHFSC
followed by 90 mL of normal saline over the first hour
and an additional 50 mL of 5% dextrose in 0.2%
sodium chloride SC over the next 2 hours (140 mL
delivered, SC total). Due to his ongoing fluid loss with
continued vomiting and diarrhea, the patient was hos-
pitalized, and IV therapy initiated. The patient im-
proved over the next 2 days but was unable to tolerate
Hospital stay
ED only
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Figure 3. Total volume delivered in emergency de-
partment (ED) was similar between non-
rescued recombinant human hyaluroni-
dase-facilitated subcutaneous (rHFSC)
and intravenous (IV) therapy.Volume 34 Number 11
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P.R. Spandorfer et al.oral fluids. Examination of the SC site did not reveal
any erythema or edema. The IV therapy was discontin-
ued, and oral fluids were tolerated; however, the pa-
tient developed a fever of 38.9°C related to the finding
of a urinary tract infection positive forKlebsiella pneu-
moniae. Five days later, he was discharged. One day
after discharge (day 8 after rHFSC fluid administra-
tion), the patient experienced a fatal cardiopulmonary
arrest. An autopsy performed determined the cause
of death was acute bronchopneumonia and compli-
cating interstitial (viral-type) pneumonia. The re-
porting investigator considered the episode of fatal
cardiopulmonary arrest to be unrelated to rHFSC
fluid administration.
Other SAEs in the rHFSC group included a case of
viral gastroenteritis and a case of pneumonia. SAEs in
the IV group included single cases of pyrexia, rotavirus
infection, ongoing dehydration, Kawasaki’s disease,
and viral syndrome. No SAEs were considered related
to study treatment.
Treatment-Related Events
At least 1 treatment-related event (TRE) was expe-
rienced by 100% (73 of 73) of rHFSC-treated patients
and 90.7% (68 of 75) of IV-treated patients (P 0.01)
Figure 5). Most TREs were considered mild to mod-
rate in severity. Although the proportion of patients
ith TREs in the rHFSC group (100%) was numeri-
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Figure 4. Successful catheterization rates according t
facilitated subcutaneous; IV  intravenousally higher than that in the IV group (90.7%), this was
November 2012primarily due to a higher incidence of infusion-site re-
actions that are expected with the SC route of fluid
administration (specifically, erythema, swelling, and
pain). Greater numbers of patients in the rHFSC group
reported infusion-site erythema (rHFSC, 74.0%; IV,
25.3%), swelling (rHFSC, 80.8%; IV, 21.3%), and
edema (rHFSC, 6.8%; IV, 1.3%) than in the IV group.
All infusion-site events were mild to moderate in sever-
ity, except for 1 case of severe infusion-site pain in the
rHFSC group. All infusion-site events resolved sponta-
neously with no additional treatment.
Pain Assessments
Pain was assessed after catheter placement and at
the end of infusion. The most frequently experienced
treatment-emergent AE for both groups was infusion-
site pain. Reports of infusion-site pain were similar in
frequency between the 2 treatment groups (mild:
rHFSC, 61.6%; IV, 66.7%; moderate: rHFSC, 15.1%;
IV, 12.0%).The data on FLACC scores (patients aged
3 years) are provided in Figures 6A and 6B at the
time of needle stick and at the end of infusion. The
results were similar between FLACC and FACES
scales.
Return Visit to ED and Subsequent Admission
Nine of 73 (12.3%) rHFSC-treated patients, 9 of 59
(15.3%) IV-treated patients, and 1 of 15 (6.7%) pa-
17/17 13/13 17/1715/18
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Clinical Therapeuticsafter initial discharge. Two of 9 patients in the rHFSC
group and 2 of 9 in the IV group were hospitalized for
continued retreatment of dehydration. No patient in
the rHFSC rescued group was readmitted for retreat-
ment of dehydration.
DISCUSSION
The primary outcome measure, mean total volume of
fluid administered at a single infusion site from the
start to the cessation of fluid administration (ED plus
inpatient hospital stay), showed that more fluid was
administered intravenously than subcutaneously and
therefore failed to meet our primary objective. The in-
vestigators did not anticipate the need to train inpa-
tient staff and develop hospital protocols to have inpa-
tients continue the rHFSC route of hydration if they
were admitted to the hospital. However, this trial also
shows that rHFSC infusion provides an effective and
reasonably well tolerated alternate route for rehydra-
tion in mild to moderately dehydrated children in the
ED (secondary outcomes). These results are consistent
with a previous pediatric study.13 As a result, it is the
pinion of the authors that the secondary outcomes
eflect the comparison between IV and SC routes of
ydration that would be of greatest interest to the
linician.
During the study, the FDA removed the restriction
n the label that limited the amount of fluid that could
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Figure 5. Adverse events (AEs) and common infusion
facilitated subcutaneous; IV  intravenous
and swelling at infusion site.e administered subcutaneously in infants and children t
22423 years old. Because the labeling change was ap-
roved without the need for additional clinical study
ata, the study design was modified to include children
p to 10 years of age so the study results could better
epresent the pediatric population in whom SC rehy-
ration is most likely to be used.
A confounder exists in this study that helps to
xplain the difference in the total volumes adminis-
ered between the 2 treatment groups. This con-
ounder is mean infusion duration (rHFSC, 3.1
ours; IV, 6.6 hours). Only 2 patients were hospital-
zed for continued rehydration therapy with an SC
ine. SC therapy is a new treatment technique, and
here were no hospital protocols for SC line use for
npatients, which resulted in IV line placement, and
hese patients were considered treatment failures.
nalysis of volumes delivered in the ED alone sup-
orts this explanation. It is important to note that
ean volume infused in the ED with rHFSC was
hown to be noninferior to IV rehydration. Simi-
arly, the mean infusion flow rate achieved with
HFSC was comparable to IV infusion in the ED.
Both rHFSC and IV routes yielded similar improve-
ents in objective clinical parameters, including im-
rovement in Gorelick dehydration scores, weight
ain, and time from fluid administration to first urine
utput. HCPs reported patients were rehydrated by
ssigned route more frequently with rHFSC therapy
Erythema† Swelling
All IV randomized (n = 75)
IV only with no rescue (n = 60)
events. rHFSC recombinant human hyaluronidase-
y general disorder or infusion-site event; †Erythema = 73)
-site
. *Anhan with IV therapy. The lower rate in the IV group
Volume 34 Number 11
P.R. Spandorfer et al.may represent the inability to establish IV access in
21.3% (16 of 75) of patients. All patients for whom an
IV infusion device could not be placed had successful
rescue with an rHFSC infusion.
The ability to obtain infusion device access fa-
vored rHFSC rehydration. Significantly more place-
ment attempts were required for IV versus rHFSC
therapy; there was a20% IV placement failure rate
for patients randomized to IV therapy. All IV access
failures occurred in children 3 years old, an obser-
vation previously described.3 No rHFSC access fail-
ures occurred in this population. No patient ran-
rHFSC therapy (n = 60) Immediately after
needle stick and infusion device insertion
IV therapy (n = 42) Immediately after needle
stick and infusion device insertion
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Figure 6. Distribution of pain scores at (A) time of
needle stick and at (B) end of infusion
according to treatment group (actual
route of administration) for patients
aged 3 years. rHFSC  recombinant
human hyaluronidase-facilitated subcu-
taneous; IV  intravenous; FLACC 
Faces, Legs, Activity, Cry, and Consol-
ability scale (range, 0–10 [0  relaxed
and comfortable, 7–10 severe discom-
fort or pain or both]). *Data missing for
1 patient; no scores recorded in 8 to 10
range; †Data missing for 3 patients; no
scores recorded in 8 to 10 range.domized to rHFSC rehydration requested to have the
November 2012SC line removed and rehydration continued through
an IV line.
Both methods of fluid delivery were reasonably well
tolerated, with mild to moderate infusion-site pain re-
lated to needle insertion being similarly reported be-
tween groups and resolving postinsertion.
A post hoc analysis was performed on the treat-
ment-received population. The original statistical anal-
ysis plan did not account for this, and there were 15
patients who were rescued with rHFSC. The results of
the post hoc analysis did not change any of the
conclusions.
Clinicians who are not familiar with SC hydration
often ask if the treatment is painful or if the family will
accept this treatment modality. This study demon-
strated that pain is comparable to IV therapy and that
families and patients are willing to receive rHFSC hy-
dration as a treatment for dehydration. However, as
this study also shows, it is important to develop rHFSC
rehydration protocols, as well as nursing policies and
procedures, before instituting this treatment modality
to ensure optimal success.
Some limitations to this study deserve discussion. At
the time the protocol was devised, the FDA limited
total SC fluid volume augmented with recombinant
human hyaluronidase in a single infusion to 200 mL in
infants and children 3 years old. Therefore, the pri-
mary end point was selected to assess total volume of
fluid delivered; however, the end point lost the clinical
importance it once held. Another limitation was that
most centers did not have protocols allowing use of an
SC line in the inpatient setting, which limited data on
rHFSC compared with IV therapy and caused an im-
balance in the amount of fluid received by the rHFSC
route in the hospital. These findings suggest that train-
ing and guidelines are needed for successful implemen-
tation of rHFSC fluid administration in the inpatient
setting. Finally, it is important to note that the results
of this study are applicable only to appropriately
selected children who have mild to moderate
dehydration.
CONCLUSIONS
This study demonstrated that in patients who required par-
enteral therapy for mild to moderate dehydration, both IV
and rHFSCfluid administrationwere effective andwell-tol-
erated methods of rehydration in the ED setting. Although
combined total volume of fluid delivered in an ED and
inpatient hospital setting was insufficient with rHFSC
2243
Clinical Therapeuticsadministration to reject inferiority compared with IV ad-
ministration, assessment of the ED-only portion did reveal
noninferiority. SChydration using rHFSC represents an ap-
propriate treatment for rehydration of children who have
mild to moderate dehydration. Based on the results of this
trial, rHFSC rehydration is a reasonable alternative to IV
fluid replacement in these select patients who have mild to
moderate dehydration in the ED. It is less invasive and is
clinically effective in the ED. rHSFC was easy to perform
and required less staff time than IV hydration. rHFSC hy-
drationmay be particularly useful for patients with difficult
IV access. Additional research in SC hydration should be
performed to validate the secondary objectives that were
shown in this study.Furthermore, SCrehydration shouldbe
considered for inclusion in future dehydration treatment al-
gorithms along with ORT and IV treatment options.
ACKNOWLEDGMENTS
The authors acknowledge Baxter Healthcare Corporation
for funding the study and Halozyme Therapeutics for con-
tributions to protocol development andmanuscript review.
Editorial support was provided by John A. Romankie-
wicz, PharmD, of Scientific Therapeutics Information, Inc,
who reviewed the draft manuscript, contributed editorial
assistance, and coordinated reviews of the manuscript with
all authors; fundingwas provided byHalozyme.Halozyme
provided critical reviewof themanuscript. The authors also
acknowledge all the patients and parents, study coordina-
tors, staff, and nurses at the participating hospitals; without
their help, performance of this study would not have been
possible.
Contributing investigators to the INFUSE-Peds II Study
Group and their participating hospitals are as follows: Neil
Reinhardt, MD (Tampa General Hospital, University of
South Florida, Tampa, Florida), George M. Maher, DO
(Memorial Children’s Hospital, South Bend, Indiana), Sha-
ronR. Smith,MD(ConnecticutChildren’sMedicalCenter,
Hartford, Connecticut), Barry Hahn, MD (Staten Island
University Hospital, Staten Island, New York), Pamela J.
Okada, MD (Children’s Medical Center Dallas, Dallas,
Texas), Ronald B. Tull, MD (North Georgia Clinical Re-
search, Dalton, Georgia), Philip R. Spandorfer, MD (Chil-
dren’s Healthcare of Atlanta, Atlanta, Georgia), David M.
Spiro,MD (OregonHealth&ScienceUniversity, Portland,
Oregon), Coburn H. Allen, MD (Baylor College of Medi-
cine/Texas Children’s Hospital, Houston, Texas), Robert
Birkhahn, MD (New YorkMethodist Hospital, Brooklyn,
New York), Vasudha Chundru, MD (UMDNJ/Robert
Wood JohnsonMedical School, NewBrunswick,New Jer-
2244sey),MarkC.Clark,MD(ArnoldPalmerHospital forChil-
dren, Orlando, Florida), Sharon E. Mace, MD (Cleveland
Clinic Foundation, Cleveland, Ohio), Harold K. Simon,
MD (Children’s Healthcare of Atlanta, Atlanta, Georgia),
Janice E. Sullivan, MD (University of Louisville, Louisville,
Kentucky),HaithamHaddad,MD(UHRainbowBabies&
Children’s Hospital, Cleveland, Ohio), Albert Nakanishi,
MD(SSMCardinalGlennonChildren’sMedicalCenter, St.
Louis, Missouri), Aveh Bastani, MD (William Beaumont
Hospital, Troy, Michigan), Waseem Hafeez, MD (Chil-
dren’sHospital atMontefiore, Bronx,NewYork), Truman
J. Milling, Jr, MD (Dell Children’s Medical Center of Cen-
tral Texas (Austin, Texas), RebeccaHutchings,MD (Osch-
nerClinicFoundation,NewOrleans,Louisiana),CarlaMa-
riaAlcid,MD(TulaneHospital forChildren,NewOrleans,
Louisiana), JamesVincent,MD(ClearLakeRegionalMed-
ical Center,Webster, Texas), and Randolph J. Cordle,MD
(CarolinasMedical Center, Charlotte, North Carolina).
Protocol development was performed by Drs.
Friend, Harb, and Lebel. Subject recruitment and data
collection was performed by Drs. Spandorfer, Mace,
Okada, Simpon, Allen, and Spiro. Data analysis was
performed by Drs. Spandorfer, Friend, Harb, and
Lebel. Manuscript preparation and revision was per-
formed by all authors.
CONFLICTS OF INTEREST
Drs. Friend, Harb, and Lebel were employed by Baxter
Healthcare during the course of this study and publi-
cation development. All study investigators received
research funds from Baxter Healthcare. Additionally,
Drs. Spandorfer, Mace, and Allen served on the Baxter
Healthcare speakers’ bureau discussing subcutaneous
rehydration in children.
The authors have indicated that they have no other
conflicts of interest regarding the content of this article.
REFERENCES
1. Owens PM, Thompson J, Elixhauser A, Ryan J. Care of
Children and Adolescents in US Hospitals. Rockville, Md:
Agency for Healthcare Research and Quality; 2003. HCUP
Fact Book No. 4; AHRQ Publication No. 04-0004.
2. Spandorfer PR, Alessandrini EA, Joffe MD, et al. Oral versus
intravenous rehydration of moderately dehydrated chil-
dren: a randomized controlled trial. Pediatrics. 2005;115:
295–301.
3. Yen K, Riegert A, Gorelick MH. Derivation of the DIVA
score: a clinical prediction rule for the identification of
Volume 34 Number 11
11
1
1
1
administered morphine in patients
1
1
1
1
1
2
Pain. 2001;89:295–300.
P.R. Spandorfer et al.children with difficult intravenous
access. Pediatr Emerg Care. 2008;24:
143–147.
4. Spandorfer PR. Subcutaneous rehy-
dration: updating a traditional tech-
nique. Pediatr Emerg Care. 2011;27:
1–7.
5. Bookbinder LH, Hofer A, Haller MF,
et al. A recombinant human enzyme
for enhanced interstitial transport of
therapeutics. J Control Rel. 2006;114:
230–241.
6. Yocum RC, Kennard D, Heiner LS.
Assessment and implication of the
allergic sensitivity to a single dose of
recombinant human hyaluronidase
injection: a double-blind, placebo-
controlled clinical trial. J Infus Nurs.
2007;30:293–299.
7. Thomas JR, Yocum RC, Haller MF, et
al. Assessing the role of human re-
combinant hyaluronidase in gravity-
driven subcutaneous hydration: the
INFUSE-LR study. J Palliat Med. 2007;
10:1312–1320.
8. Dychter SS, Ebel D, Mead TR, et al.
Comparison of the tolerability of
recombinant human hyaluronidase
 normal saline and recombinant
human hyaluronidase  lactated
ringer’s solution administered subcu-
taneously: a Phase IV, double-blind,
randomized pilot study in healthy
volunteers. Curr Ther Res Clin Exp.
2009;70:421–438.
9. Soremekun OA, Shear ML, Patel S,
et al. Rapid vascular glucose uptake
via enzyme-assisted subcutaneous
infusion: Enzyme-Assisted Subcuta-
neous Infusion Access Study. Am J
Emerg Med. 2009;27:1072–1080.
0. Thomas JR, Wallace MS, Yocum RC,
et al. Subcutaneous administration
of morphine recombinant human
hyaluronidase (recombinant hyal-
uronidase) enhances morphine ab-
sorption in palliative care patients
and healthy volunteers. Poster pre-
sented at: 2007 Annual Meeting and
Industrial Exhibition of the Infusion
Nurses Society; June 2–7, 2007; Or-
lando, Fla.
November 20121. Thomas JR, Yocum RC, Haller MF,
et al. The INFUSE-Morphine IIB
study: use of recombinant human
hyaluronidase (rHuPH20) to en-
hance the absorption of subcutane-
ous morphine in healthy volunteers.
J Pain Symptom Manage. 2009;38:673–
682.
2. Harb G, Lebel F, Battikha J, et al.
Safety and pharmacokinetics of sub-
cutaneous ceftriaxone administered
with or without recombinant hu-
man hyaluronidase (rHuPH20) ver-
sus intravenous ceftriaxone adminis-
tration in adult volunteers. Curr Med
Res Opin. 2010;26:279–288.
3. Allen CH, Etzwiler LS, Miller MK, et
al; Increased Flow Utilizing Subcuta-
neously-Enabled Pediatric Rehydra-
tion Study Collaborative Research
Group. Recombinant human hyal-
uronidase-enabled subcutaneous
pediatric rehydration. Pediatrics.
2009;124:e858–e867.
4. Thomas JR, Wallace MS, Yocum RC,
et al. The INFUSE-Morphine Study:
use of recombinant human hyal-
uronidase (rHuPH20) to enhance
the absorption of subcutaneouslyLLC.comwith advanced illness. J Pain Symptom
Manage. 2009;38:663–672.
5. Pirrello RD, Ting Chen C, Thomas
SH. Initial experiences with subcuta-
neous recombinant human hyal-
uronidase. J Palliat Med. 2007;10:
861–864.
6. King CK, Glass R, Bresee JS, et al.
Centers for Disease Control and
Prevention. Managing acute gastro-
enteritis among children: oral rehy-
dration, maintenance, and nutri-
tional therapy. MMWR Recomm Rep.
2003;52:1–16.
7. Nelson WE. Fluid therapy. In: Nel-
son WE, Behrman RE, Kliegman
RM, Arvin AM, eds. Nelson Text-
book of Pediatrics. Philadelphia,
Penn: WB Saunders Company;
1996:206–210.
8. Gorelick MH, Shaw KN, Murphy
KO. Validity and reliability of clinical
signs in the diagnosis of dehydration
in children. Pediatrics. 1997;99:E6.
9. Merkel S, Voepel-Lewis T, Malviya S.
Pain assessment in infants and young
children: the FLACC scale. Am J Nurs.
2002;102:55–58.
0. Wong DL, Baker CM. Smiling faces
as anchor for pain intensity scales.Address correspondence to: Philip R. Spandorfer, MD, MSCE, Children’s
Healthcare of Atlanta at Scottish Rite, Emergency Department, 1001 John-
son Ferry Road NE, Atlanta, GA 30342. E-mail: Pip_spandorfer@PEMA-2245
